BioMarin Pharmaceutical Inc. diskutieren
BioMarin Pharmaceutical Inc.
WKN: 924801 / Symbol: BMRN / Name: BioMarin Pharmaceutical / Aktie / Pharmazeutika / Large Cap /
50,90 €
-0,86 %
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Barclays PLC from $110.00 to $86.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "outperform" rating re-affirmed by analysts at Raymond James. They now have a $79.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at UBS Group AG from $104.00 to $106.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Evercore ISI from $115.00 to $105.00. They now have an "outperform" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at JPMorgan Chase & Co. from $110.00 to $109.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at Cantor Fitzgerald from $110.00 to $90.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $95.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $90.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Piper Sandler from $122.00 to $126.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at Bank of America Co. from $99.00 to $103.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at UBS Group AG from $109.00 to $113.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $90.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at Oppenheimer Holdings Inc. from a "market perform" rating to an "outperform" rating. They now have a $98.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $124.00 to $104.00. They now have a "buy" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is now covered by analysts at Morgan Stanley. They set an "overweight" rating and a $97.00 price target on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) had its price target raised by analysts at JPMorgan Chase & Co. from $108.00 to $113.00. They now have an "overweight" rating on the stock.
Ratings data for BMRN provided by MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was given a new $95.00 price target on by analysts at Wolfe Research. They now have an "outperform" rating on the stock.
Ratings data for BMRN provided by MarketBeat
Neueste Beiträge
SVB_Leerink_LLC in Ultragenyx Pharmaceutical Inc. diskutieren